Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -5.96, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 31.70M shares, increasing 14.93% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 23.22K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.25.